| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/24/2004 | US20040122062 such as 2-amino-N-(2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl)-isobutyramide |
| 06/24/2004 | US20040122061 Inhibitors of post-amadori advanced glycation end products |
| 06/24/2004 | US20040122060 Prophylaxis of non-insulin dependent diabetes, by administering nontoxic drug mixtures comprising sulphonylureas, hyperglycemic and antilipemic agents |
| 06/24/2004 | US20040122059 PPAR-gamma ligands in the treatment of asthma and allergies |
| 06/24/2004 | US20040122058 2'-amino-3'-methoxyflavone, 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide, butanedinitrile bis(2-aminophenylthio)methylene or 4-4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)- H-imidazole; antiinflammatory agents |
| 06/24/2004 | US20040122057 Novel mandelic acid derivatives |
| 06/24/2004 | US20040122056 dissolving crude omeprazole in a solvent or a mixture of solvents in which omeprazole is freely soluble, and precipitating crystal form of omeprazole with a solvent in which omeprazole is poorly soluble. |
| 06/24/2004 | US20040122055 C10 carbonate taxane compositions |
| 06/24/2004 | US20040122054 Alpha glucosidase inhibitor use |
| 06/24/2004 | US20040122052 Isoindolin-1-one and Isoindoline-1,3-dione substituted in the 2-position with a 2,6-dioxo-3-hydroxypiperidin-5-yl group or derivative; selectively inhibit TNF alpha, useful in treating inflammation and effecting relaxation of airway smooth muscle |
| 06/24/2004 | US20040122051 Methods for treating cognitive impairments or dementia |
| 06/24/2004 | US20040122049 heterocyclic derivatives containing N-substituted piperidine ring and an amide or urea group; useful for treating rheumatic arthritis |
| 06/24/2004 | US20040122048 Stabilized pharmaceutical composition containing basic excipients |
| 06/24/2004 | US20040122047 Substituted tetrahydroisoquinolines |
| 06/24/2004 | US20040122045 administering {cyclopentanecarboxamide, 4-[4-[[(1R)-1-[(3-chloro-2-thienyl)methyl]propyl]amino]-7H-pyrrolo[2,3,-d]pyrimidin-7-yl]-N-ethyl-2,3-dihydroxy compound beginning at a time less than 10 min. after the onset reperfusion and 10 min. before |
| 06/24/2004 | US20040122044 Utilization of substituted imidazo [1,2-A]-pyridin-3-yl-amide and imidazo [1,2-A]-pyridin-3-yl-amine compounds in pharmaceutical formulations |
| 06/24/2004 | US20040122041 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| 06/24/2004 | US20040122040 Bicyclic guanidine derivatives and therapeutic uses thereof |
| 06/24/2004 | US20040122037 Strong anti-depressant activity without being sedative; serotonin (5-HT) reuptake inhibitor activity in combination with additional alpha 2-adrenoceptor antagonist activity |
| 06/24/2004 | US20040122036 Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents |
| 06/24/2004 | US20040122035 selective inhibitors of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase-5 (PDE5); sexual disorders, cardiovascular disorders; 1-(2H-benzo[d]1,3-dioxolan-5-yl)(1,2,3,4-tetrahydro- beta -carbolin-2-yl)-2-naphthyl ketone for example |
| 06/24/2004 | US20040122034 Polymorph forms of n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxopyrrolidin-1-1yl)acetamide |
| 06/24/2004 | US20040122033 Combination therapy for the treatment of obesity |
| 06/24/2004 | US20040122032 for treating neurodegenerative disorders; mixture with other active ingredients; 1-{2-(3'-chlorobiphenyl-4-yl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine for example; Alzheimer's disease, cerebral edema |
| 06/24/2004 | US20040122031 Thiazolidinedione and pharmaceutical composition comprising the same |
| 06/24/2004 | US20040122030 Substituted phthalimide and isoquinoline derivatives; thalidomide analogs that lack the piperidine-2,6-dione moiety of thalidomide |
| 06/24/2004 | US20040122027 Use of pyridoindolone derivatives for preparing anticancer medicines |
| 06/24/2004 | US20040122025 4-(4-Fluorophenyl)-3-(2-methylsulfanyl-pyrimidin-4-yl)-2H-isoxazol-5-one for example; treating rheumatoid arthritis, osteoarthritis and congestive heart failure |
| 06/24/2004 | US20040122024 Effective against mutations; such as 2,3-Dihydro-4-ethyl-1-(3-methylphenylamino)-5-phenyl-1H-imidazole-2-thione |
| 06/24/2004 | US20040122023 Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine |
| 06/24/2004 | US20040122022 Compositions and methods for treating upper respiratory congestion |
| 06/24/2004 | US20040122021 High optical purity of both levoratatory and dextrorotatory forms; simple, economic synthesis |
| 06/24/2004 | US20040122020 Novel amides, preparation and therapeutic use as modulators of ccr-receptor activity |
| 06/24/2004 | US20040122018 Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives; use in combination with antineoplastic agents such as cisplatin |
| 06/24/2004 | US20040122017 Melanin concentrating hormone (MCH) modulators; metabolic and eating disorders |
| 06/24/2004 | US20040122015 Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents |
| 06/24/2004 | US20040122011 such as 3-[3-[N-isopropyl-N-(4-methoxyphenyl-sulfonyl)amino]-phenyl]-3-(3-pyridyl)-2(E)-propenohydroxamic acid; for treatment/prevention of neoplasia/inflammation; kits |
| 06/24/2004 | US20040122010 Treatment of neuropathy |
| 06/24/2004 | US20040122009 formed via cyanuric chloride; for treatment of cancer and proliferative diseases |
| 06/24/2004 | US20040122008 such as 1-[3-(4-morpholinyl)propyl]-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole; antiinflammatory agents |
| 06/24/2004 | US20040122006 such as 7-[(2-aminophenyl)sulfanyl]-2H-1,4-benzoxazin-3(4H)-one; oxidation/reduction; deblocking/deprotectiing; cardiovascular disorders |
| 06/24/2004 | US20040122005 Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme |
| 06/24/2004 | US20040122004 such as (1R,2R)-N-[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]-2-(4-{[{[ethyl(2-hydroxyethyl)amino]carbonyl}(4-fluorophenyl)amino]methyl}phenyl)cyclohexanecarboxamide; for prevention/treatment of cardiovascular disorders |
| 06/24/2004 | US20040122002 Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof |
| 06/24/2004 | US20040122001 Pharmaceutical compounds |
| 06/24/2004 | US20040122000 Inhibitors of aspartyl protease |
| 06/24/2004 | US20040121998 CRF antagonistic quino- and quinazolines |
| 06/24/2004 | US20040121997 20-hydroxyeicosatetraenoic acid production inhibitors |
| 06/24/2004 | US20040121996 Benzoxazin-3-ones and derivatives thereof as therapeutic agents |
| 06/24/2004 | US20040121995 such as trifluoromethanesulfonic acid, N-[4-(2,5-difluorophenyl)-4-(6-trifluoromethyl-pyridine-3-sulfonyl)-cyclohexyl]-amide; for treatment/prevention of Alzheimer's disease |
| 06/24/2004 | US20040121993 for the reduction of cholesterol in blood, and treatment of fatty liver, hyperglycemia and diabetes |
| 06/24/2004 | US20040121992 Therapeutic methods of reducing cholesterol accumulation |
| 06/24/2004 | US20040121991 for treatment of inflammatory bowel disease/Crohn's disease/cachexia; for sustained release |
| 06/24/2004 | US20040121988 administering pyridoxal-5'-phosphate, pyridoxal, pyridoxine, or pyridoxamine |
| 06/24/2004 | US20040121987 Liposomal analgesic formulation and use |
| 06/24/2004 | US20040121984 For inhibiting binding of chlamydia to a mammalian cell |
| 06/24/2004 | US20040121983 Method for treating leishmaniasis using methyl-beta-cyclodextrin |
| 06/24/2004 | US20040121982 Biocompatible dialysis fluids containing icodextrins |
| 06/24/2004 | US20040121981 Administering therapeutically effective amount of a compound which binds to a galectin |
| 06/24/2004 | US20040121980 For therapy of Hepatitis C Virus (HCV) mediated diseases |
| 06/24/2004 | US20040121979 Pharmaceutically active uridine esters |
| 06/24/2004 | US20040121978 Adenosine A3 receptor agonists |
| 06/24/2004 | US20040121975 Hepatitis C virus assays |
| 06/24/2004 | US20040121972 Methylenetetrahydrofolate reductase inhibitors and uses thereof |
| 06/24/2004 | US20040121969 Antiviral nucleoside derivatives |
| 06/24/2004 | US20040121968 Antiangiogenesis by inhibiting protein kinase CK2 activity |
| 06/24/2004 | US20040121965 Treating, inhibiting the growth of, or eradicating a tumor in a mammal in need thereof wherein tumor is resistant to at least one chemotherapeutic agent by providing to mammal an effective amount of a hemiasterlin compound |
| 06/24/2004 | US20040121963 Composition for inhibiting hiv activity extracted from paecilomyces sp. (tochu-kaso) j300 |
| 06/24/2004 | US20040121962 Prodrugs of excitatory amino acids |
| 06/24/2004 | US20040121961 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer |
| 06/24/2004 | US20040121958 Methods of alleviating neuropathic pain |
| 06/24/2004 | US20040121956 For therapy of diseases in animals and for the control of insects that are injurious or harmful to plants or animals |
| 06/24/2004 | US20040121940 Anticancer prodrugs, enhance enzymatic activation rates |
| 06/24/2004 | US20040121463 Methods and compositions for modulating apoptosis |
| 06/24/2004 | US20040121422 Diagnosis and treatment of human kidney diseases |
| 06/24/2004 | US20040121406 Methods and formulations for increasing the affinity of a1 adenosine receptor ligands for the a1 adenosine receptor |
| 06/24/2004 | US20040121376 Antisense modulation of interleukin-5 signal transduction |
| 06/24/2004 | US20040121372 Comprises receptors for advanced glycation endproduct polypeptides for use in diagnosis and treatment inflammation, infection, sepsis, autoimmune, atherosclerotic and nervous system disorders |
| 06/24/2004 | US20040121348 Compositions and methods for treating pancreatic cancer |
| 06/24/2004 | US20040121316 Method and compositions for identifying anti-HIV therapeutic compounds |
| 06/24/2004 | US20040121030 Extract from the pods of lupin seeds containing lupeol |
| 06/24/2004 | US20040121028 Plant based agents as bioavailability / bioefficacy enhancers for drugs and nutraceuticals |
| 06/24/2004 | US20040121025 comprises vanadium, ipriflavone, homocysteine inhibiting agent, and an absorbable calcium salt in carrier; side effect reduction |
| 06/24/2004 | US20040121024 comprises glucosamine sulfate, nettle leaf, quercetin, curcumin extract/curcuminoids, selenium, zinc, vitamin C (calcium ascorbate) and grape seed extract |
| 06/24/2004 | US20040121023 antiinflammatory agents; for treating joints, muscles, tendons, and/or ligaments |
| 06/24/2004 | US20040121015 active substanece administered to a high fat use environment such as the human gastrointestinal tract following a high fat meal; active-substance-containing core and an asymmetric polymeric coating (cellulose acetates) |
| 06/24/2004 | US20040121012 Sustained release matrix for high-dose insoluble drugs |
| 06/24/2004 | US20040121011 Methods for making and delivering Rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof |
| 06/24/2004 | US20040121010 once-a-day oral milnacipran pulsatile release when administered orally, releases drug in spaced apart "pulses", this delivery profile reduces gastrointestinal side effects by minimizing exposure of the internal mucosal surfaces to the drug |
| 06/24/2004 | US20040121009 Method of modifying the release profile of sustained release compositions |
| 06/24/2004 | US20040121008 Process for producing sustained release preparation |
| 06/24/2004 | US20040121007 spray-granulating the bisphosphonate, a part of filler and disintegrant with a solution of the binder in purified water, drying the spray granulated material, screening, mixing remaining filler, lubricants, flow controller, compressing into tablet |
| 06/24/2004 | US20040121004 protecting the gastrointestinal tract from non-steroidal antiinflammatory drug therapy by administering a NSAID in combination with a buffer and a proton pump inhibitor in a single non-enterically coated dosage form |
| 06/24/2004 | US20040121001 Orally adminstrable opioid formulations having extended duration of effect |
| 06/24/2004 | US20040120999 Liposome containing remedy for vascular disease |
| 06/24/2004 | US20040120997 liposomes containing a sterol skeleton based compound wherein one or several amphoteric groups with an isoelectric point of between 4 and 9 are substituted on the 3rd position of the ring system |
| 06/24/2004 | US20040120996 administering as a transdermal patch, containing oxybutynin to a patient a duration about 24 to 96 hours to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from 0.5:1 to 5:1 to treat overactive bladder |
| 06/24/2004 | US20040120995 a non-woven medical absorbent and the pergolide is dissolved in an aqueous based solvent |
| 06/24/2004 | US20040120994 polymer matrix contains the sex hormone testosterone and a mixture of a penetration-enhancing substance selected from fatty alcohol esters and fatty acid esters, and at least one readily volatile penetration-enhancing agent |
| 06/24/2004 | US20040120987 Process and composition for controlling fecal hair excretion and trichobezoar formation |